Cephalon required to disclose physician payments

Share this article:

By entering into a corporate integrity agreement (CIA) with the Department of Health and Human Services, Cephalon became the first drugmaker required by law to disclose payments to physicians, the Dow Jones Newswires reported.

The five-year CIA stipulates that Cephalon post all payments to physicians “in a prominent position on its website,” in an “easily accessible and readily searchable listing.” The payment disclosures are to be posted by January 31, 2010. 

The agreement comes after Cephalon announced plans to plead guilty for promoting three medications off-label: Actiq, a pain medication; Provigil, a sleep apnea drug; and Gabitril, for epilepsy. As a result, the company will pay $443.9 million to settle state and federal probes, according to Dow Jones Newswires report.

“This case is about making sure that pharmaceutical companies market their drugs within the rules established to protect us all,” said Laurie Magid, acting US Attorney for the Eastern District of Pennsylvania, in the report.

In a Q&A on the matter found on Cephalon's website, the company said it had “worked diligently to develop an effective compliance program related to our promotional practices and product-related services. We believe that the enhanced compliance program now in place will more effectively ensure that we are in compliance with all applicable laws and regulations.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...